Dicerna pushed up price and contacted other suitors before making deal with Novo Nordisk
Novo Nordisk wasn't alone in expressing interest in acquiring biotech business Dicerna, but after a bidding war, the Danish pharmaceutical company's offer was the most economically attractive, documents reveal.
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY DANIEL PEDERSEN
When the hammer came down, Novo Nordisk's final bid for US-based Dicerna far exceeded its initial offer.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk acquires Dicerna for USD 3.3bn
For subscribers
